Nxera Pharma Swings to Nine-Month Net Profit of JPY 2.33 Billion

Bitget2026/10/30 06:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nxera Pharma swung to a net profit of JPY 2.33 billion for the nine months ended September 30, 2026.
Revenue rose 27% year-over-year to JPY 27.74 billion, while milestone revenue more than doubled to JPY 9.5 billion.
In October, it licensed Fabry disease candidate lucerastat from Idorsia, with regulatory filings targeted as early as 2029.
The full-year 2026 revenue forecast remains unchanged at JPY 33.8 billion to JPY 48.8 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nxera Pharma Swings to Nine-Month Net Profit of JPY 2.33 Billion

You may also like

Crypto prices